T1	Participants 513 557	202 academic medical centres in 24 countries
T2	Participants 559 671	Patients with previously treated non-small-cell lung cancer with PD-L1 expression on at least 1% of tumour cells
T3	Participants 1319 1344	we enrolled 1034 patients
